Drug Search Results
More Filters [+]

Ridaforolimus

Alternative Names: ridaforolimus, mk-8669, ap23573, mk8669
Latest Update: 2024-11-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: mTOR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ridaforolimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Soft Tissue Cancer|Bone Cancer|Sarcoma|Osteosarcoma

Phase 2: Sarcoma|Breast Cancer|Endometrial Cancer|Prostate Cancer|Oncology Unspecified|Leiomyosarcoma|Osteosarcoma|Non-Small-Cell Lung Cancer|Liposarcoma|Myeloid Leukemia|Myelodysplastic Syndrome|Lymphoma|Myelofibrosis

Phase 1: Lymphoma|Non-Small-Cell Lung Cancer|Sarcoma|Ovarian Cancer|Glioma|Glioblastoma|Gliosarcoma|Oncology Solid Tumor Unspecified|Heart Cancer|Oncology Unspecified|Multiple Myeloma|Endometrial Cancer|Prostate Cancer|Breast Cancer|Peritoneal Cancer|Hepatic Insufficiency|Fallopian Tube Cancer|Primary Central Nervous System Lymphoma|Liver Failure|Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IoNIR-002

N/A

Not yet recruiting

Coronary Artery Disease|Coronary Stenosis

2026-09-01

CHAMPIONSHIP

N/A

Recruiting

Peripheral Arterial Disease

2025-08-30

IonMAN

N/A

Active, not recruiting

Non-ST Elevated Myocardial Infarction|Coronary Disease|Coronary Stenosis

2024-09-30

EluNIR-005

N/A

Completed

Coronary Stenosis|Myocardial Ischemia

2021-11-02

Recent News Events